How Analysts Feel About Motif Bio plc (LON:MTFB)?

October 13, 2018 - By Marie Mckinney

Motif Bio plc (LON:MTFB) Ratings Coverage

Among 2 analysts covering Motif Bio Plc (LON:MTFB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Motif Bio Plc had 25 analyst reports since May 1, 2018 according to SRatingsIntel. As per Tuesday, May 1, the company rating was maintained by Peel Hunt. The stock of Motif Bio plc (LON:MTFB) earned “Buy” rating by Northland Capital on Tuesday, September 25. Northland Capital maintained it with “Buy” rating and GBX 116 target in Monday, July 16 report. The rating was maintained by Northland Capital on Friday, May 18 with “Buy”. The firm earned “Buy” rating on Monday, June 11 by Northland Capital. The firm earned “Buy” rating on Wednesday, August 1 by Peel Hunt. The company was maintained on Wednesday, August 8 by Northland Capital. The stock of Motif Bio plc (LON:MTFB) earned “Buy” rating by Northland Capital on Wednesday, May 23. Peel Hunt maintained the stock with “Buy” rating in Thursday, June 14 report. On Tuesday, July 3 the stock rating was maintained by Peel Hunt with “Buy”. Below is a list of Motif Bio plc (LON:MTFB) latest ratings and price target changes.

03/10/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 95.00 Maintain
28/09/2018 Broker: Northland Capital Rating: Buy Maintain
25/09/2018 Broker: Northland Capital Rating: Buy Maintain
25/09/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 95.00 Maintain
20/09/2018 Broker: Northland Capital Rating: Buy Maintain
05/09/2018 Broker: Northland Capital Rating: Buy Old Target: GBX 116.00 Maintain
04/09/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 102.00 Maintain
17/08/2018 Broker: Northland Capital Rating: Buy Old Target: GBX 116.00 Maintain
14/08/2018 Broker: Northland Capital Rating: Buy Old Target: GBX 116.00 Maintain
14/08/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 102.00 Maintain

The stock increased 2.65% or GBX 0.8 during the last trading session, reaching GBX 31. About 405,485 shares traded. Motif Bio plc (LON:MTFB) has 0.00% since October 13, 2017 and is . It has underperformed by 15.62% the S&P500.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company has market cap of 91.97 million GBP. The firm develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. It currently has negative earnings. The Company’s lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>